china introduced digital currency snippets

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)Hongxin Electronics: Promote the technical research and development and product supply of folding mobile phone reels with Xiaomi. Hongxin Electronics officially announced today that recently, the 2024 Xiaomi Global Core Supplier Conference was held in Beijing Yanqi Lake International Convention & Exhibition Center. Under the background that Xiaomi's strategy of "people, cars and homes are all ecological" continues to deepen, Hongxin Electronics will closely follow Xiaomi's footsteps, actively expand emerging fields such as home appliances and automobiles, and provide all-round support and services in flexible electronics for Xiaomi's intelligent hardware all-ecological products. At present, in the face of the booming folding mobile phone market, Hongxin Electronics and Xiaomi jointly promote the technology research and development and product supply of folding mobile phone reels. According to reports, in the era of vigorous development of artificial intelligence and digital economy, at present, Hongxin Electronics has deeply laid out frontier fields such as AI mobile phones, AIPC, smart cars, smart homes, smart wearable devices, robots, industrial control, medical care and meta-universe.

From January to October, the total output of lithium batteries in China increased by 16% year-on-year. According to the Ministry of Industry and Information Technology, China's lithium-ion battery industry continued to grow from January to October 2024. According to the announcement of lithium battery industry norms, enterprise information and industry associations, the total output of lithium batteries in China from January to October was 890GWh, up 16% year-on-year. According to the data of the National Bureau of Statistics, the profit of China's lithium battery manufacturing industry increased by 39.4% from January to October. In the battery sector, the output of energy storage lithium batteries exceeded 200GWh from January to October. The loading capacity of power lithium batteries for new energy vehicles is about 405GWh. From January to October, the total export of lithium batteries in China reached 350.2 billion yuan, down 9.2% year-on-year, and the decline was 3.3 percentage points narrower than that in January-June.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.

Chen Guo, China Securities: The 2025 policy will focus on expanding domestic demand and AI+ in all directions, and the Central Economic Work Conference will be held in Beijing from December 11th to 12th. Chen Guo, chief strategy officer of China Securities, said that the meeting had seven highlights, including clarifying the growth target and fiscal and monetary policy measures, expanding domestic demand in all directions as the top priority of the policy, focusing on "AI+" in science and technology, focusing on implementation of reform measures, paying attention to coping with external shocks in opening up, strengthening the expression of real estate policies, and increasing efforts to improve people's livelihood. Chen Guo said that further RRR cuts and interest rate cuts from the end of 2024 to 2025 are worth looking forward to, and the easing of the liquidity environment has become a market consensus. However, this does not mean that liquidity is rampant, because the growth of money supply in the scale of social financing still continues the requirement of matching the expected target of the overall price level of economic growth. Chen Guo believes that the 2025 policy will focus on expanding domestic demand and AI+ in an all-round way, and the strength and direction of the policy are in line with expectations. With the support of policy expectations and liquidity, it is expected that the market will continue to show the characteristics of volatility. From the perspective of investment strategy, Chen Guo suggested focusing on non-bank finance, real estate chain, consumer electronics, machinery, construction, building materials, steel, social services, catering chain and other sectors. In terms of theme, it is suggested to pay attention to investment opportunities such as "duality" and "two innovations", supply-side optimization, new quality productivity, market value management of state-owned enterprises and CSI A500 index.Hyundai Motor set up 200 million technology companies in Shanghai, including a number of AI-related businesses. According to Tianyancha App, Hyundai Kemo (Shanghai) Technology Co., Ltd. was recently established, with NOH YONG HO as the legal representative and a registered capital of 213 million RMB. Its business scope includes application system integration services in artificial intelligence industry, Internet of Things application services, data processing services, artificial intelligence basic software development, artificial intelligence application software development, artificial intelligence theory and algorithm software development, etc. According to shareholder information, the company is wholly owned by Hyundai Motor Co., Ltd.On the 13th, the 30-year treasury bond futures rose by 0.60%, and the latest main contract positions changed as follows. According to the data of the exchange, as of December 13th, the main contract 30-year treasury bond futures closed at 2503, up or down by +0.60%, with a turnover of 71,900 lots. The position data showed that the top 20 seats were clear, and the difference position was 3,777 lots. The total number of 30-year treasury bond futures contracts was 82,700 lots, an increase of 4,416 lots over the previous day. The first 20 seats in the contract held 78,000 lots, a decrease of 1,313 lots from the previous day. The top 20 seats in the contract held 85,000 short positions, a decrease of 1,049 lots from the previous day. (Sina Futures)